Aydın Murat, Yorubulut Mehmet, Başarır Kerem, Arıkan Murat, Binnet Mehmet Serdar
Department of Orthopedics and Traumatology, Amasya Merzifon Public Hospital Medicine, Amasya, Turkey.
Department of Radiology, Primer Medical Imaging Center, Ankara, Turkey.
Acta Orthop Traumatol Turc. 2020 Jan;54(1):66-73. doi: 10.5152/j.aott.2020.01.347.
The aim of this study was compare the clinical success of treatments for avascular necrosis and osteochondritis dissecans in cases who underwent matrix autologous chondrocyte implantations, and evaluate cartilage thickness on the clinical outcomes after implantation.
A total of 37 patients (29 men, and 8 women; mean age: 23.8 years (16-38)) were treated prospectively with a two-stage matrix autologous chondrocyte implantation (avascular necrosis, n=21; osteochondritis dissecans, n=18). Clinical improvements and follows-up were assessed based on the patients' International Cartilage Repair Society (ICRS) scores with simultaneous cartilage thickness measurement using short-TI inversion recovery magnetic resonance imaging. The patients were divided into four subgroups based on their clinical scores, as group D <65 points, Group C 65-83 points, Group B 84-90 and Group A ≥90.
The mean ICRS score was 28.33±7.14 in the preoperative period in the avascular necrosis group, which increased to 70.88±12.61 at 60 months; while the mean ICRS score increased from 29.75±7.15 preoperatively to 87.58±12.83 at 60 months in the osteochondritis dissecans group. A statistically significant difference in the ICRS scores was noted between the two groups, and also between the ICRS scores and cartilage thicknesses of the subgroups (p<0.05).
Our study results revealed that greater clinical improvement was achieved in patients with osteochondritis dissecans undergoing matrix autologous chondrocyte implantation than in those with avascular necrosis. In addition, cartilage thickness greater than 3.7 mm following an autologous chondrocyte transplantation showed excellent clinical improvement.
Level III, Therapeutic Study.
本研究旨在比较接受基质自体软骨细胞植入术的无血管性坏死和剥脱性骨软骨炎病例的治疗临床成功率,并评估植入后软骨厚度对临床结果的影响。
共有37例患者(29例男性,8例女性;平均年龄:23.8岁(16 - 38岁))接受了两阶段基质自体软骨细胞植入术(无血管性坏死,n = 21;剥脱性骨软骨炎,n = 18)的前瞻性治疗。基于患者的国际软骨修复协会(ICRS)评分评估临床改善情况并进行随访,同时使用短TI反转恢复磁共振成像测量软骨厚度。根据临床评分将患者分为四个亚组,即D组<65分,C组65 - 83分,B组84 - 90分和A组≥90分。
无血管性坏死组术前平均ICRS评分为28.33±7.14,60个月时增至70.88±12.61;而剥脱性骨软骨炎组术前平均ICRS评分从29.75±7.15增至60个月时的87.58±12.83。两组间ICRS评分以及亚组的ICRS评分与软骨厚度之间均存在统计学显著差异(p<0.05)。
我们的研究结果显示,接受基质自体软骨细胞植入术的剥脱性骨软骨炎患者比无血管性坏死患者取得了更大的临床改善。此外,自体软骨细胞移植后软骨厚度大于3.7 mm显示出极佳的临床改善。
III级,治疗性研究。